1127 related articles for article (PubMed ID: 36601120)
21. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
Chen Z; Chen Y; Peng L; Wang X; Tang N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028694
[TBL] [Abstract][Full Text] [Related]
22. The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.
Yang Y; Chen D; Zhao B; Ren L; Huang R; Feng B; Chen H
Cancer Med; 2023 Apr; 12(8):9282-9292. PubMed ID: 36965092
[TBL] [Abstract][Full Text] [Related]
23. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
24. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
25. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
[TBL] [Abstract][Full Text] [Related]
26. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
27. RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion.
Zhuang Q; Dai Z; Xu X; Bai S; Zhang Y; Zheng Y; Xing X; Hu E; Wang Y; Guo W; Zhao B; Zeng Y; Liu X
Cancer Res; 2024 Feb; 84(3):405-418. PubMed ID: 37963197
[TBL] [Abstract][Full Text] [Related]
28. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
[TBL] [Abstract][Full Text] [Related]
29. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
30. S100A9
Tu X; Chen L; Zheng Y; Mu C; Zhang Z; Wang F; Ren Y; Duan Y; Zhang H; Tong Z; Liu L; Sun X; Zhao P; Wang L; Feng X; Fang W; Liu X
J Exp Clin Cancer Res; 2024 Mar; 43(1):72. PubMed ID: 38454445
[TBL] [Abstract][Full Text] [Related]
31. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
[TBL] [Abstract][Full Text] [Related]
32. CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer.
Niu X; Wang W; Liang T; Li S; Yang C; Xu X; Li L; Liu S
Cancer Sci; 2022 Jan; 113(1):28-40. PubMed ID: 34727389
[TBL] [Abstract][Full Text] [Related]
33. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J
Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054
[TBL] [Abstract][Full Text] [Related]
34. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract][Full Text] [Related]
35. Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma.
Zhou Z; Li X; Yang G; Wang J; Li B; Huang Y; Yan J; Tao K
Theranostics; 2023; 13(10):3371-3386. PubMed ID: 37351175
[No Abstract] [Full Text] [Related]
36. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
37. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
38. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
39. Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma.
Liu X; Zhou J; Wu H; Chen S; Zhang L; Tang W; Duan L; Wang Y; McCabe E; Hu M; Yu Z; Liu H; Choi CHJ; Sung JJ; Huang L; Liu R; Cheng AS
Mol Ther; 2023 Jan; 31(1):119-133. PubMed ID: 36146933
[TBL] [Abstract][Full Text] [Related]
40. Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells.
Cho S; Kim W; Yoo D; Han Y; Hwang H; Kim S; Kim J; Park S; Park Y; Jo H; Pyun JC; Lee M
Sci Rep; 2024 Jan; 14(1):1751. PubMed ID: 38243049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
